

HIVQUAL-Uganda Adult Indicators for Round 1 and 2 Data Collection			
Eligibility: All patients with HIV seen at least once in the clinic during the past 6 months.			
Indicator	Definition	Numerator	Denominator
Continuity of Care	A clinical visit is an encounter between a patient and a health-care provider.	The number of patients with a clinical visit (encounter with health care provider) during each 3 month quarter.	Number of patients with at least 1 visit (encounter with a health care provider) during the 6 month review period
HIV Monitoring	A CD4 test measures a patient's level of immune suppression. All CD4 test results and date of tests during the review period should be recorded.	The number of patients with a CD4 count during the past 6 months (or 6 month interval)	The number of patients with at least 1 visit during the review period
ARV Therapy	ART scale-up has occurred in Uganda. Every patient eligible should have access to ART.	The number of patients who are eligible and receiving ARV therapy during the review period or at the time of death	All patients meeting MOH criteria for eligibility of HAART (CD4 < 200 or WHO Stage 3 or 4)
ART Adherence	All patients receiving ART during the review period and are receiving it at the end of the review period or at the time of death.	The number of patients who have had an adherence assessment during the 6 month review period or at time of death	The number of patients receiving ART during the 6 month review period or at time of death
Cotrimoxazole Prophylaxis	Trimethoprim-sulphamethoxazole (Cotrimoxazole, Septrin) taken once daily is recommended as routine prophylaxis for HIV-infected patients.	The number of patients who have been prescribed cotrimoxazole* during the 6 month review period and are still receiving it at the end of the review period or at the time of death	The number of patients with at least 1 visit during the 6 month review period*
TB Clinical Symptom Assessment	The national guidelines recommend initial TB screening by questioning for the existence of a cough of 3 weeks duration.	The number of patients who have been screened** for TB during the review period	The number of patients not on TB treatment who visited the clinic at least once during the review period
TB Diagnostic Evaluation		The number of patients who have been assessed for TB during the review period	The number of patients with signs and symptoms of TB during the review period
Prevention Education	Prevention education comprises a variety of activities, including education and counseling to prevent sexual transmission of HIV (including condom use), mother-to-child transmission of HIV, abstinence and faithfulness, etc.	The number of patients who have received prevention education during the past 3 months	The number of patients with at least 1 clinic visit during the 6 month review period

*All HIV-infected patients are eligible for Cotrimoxazole Prophylaxis

**TB Screening: questioning for the existence of a cough of >3 weeks duration, weight loss, hemoptysis, night sweats, evening fevers

HIVQUAL-Uganda Pediatric Indicators and Eligibility

Eligibility: All HIV-infected children aged 0 to <15 years old who visited the clinic at least once during the review period

Indicator	Definition	Numerator	Denominator
Continuity of Care:	A clinical visit is an encounter between a patient and a doctor, a nurse or any clinical health provider. This is the definition of an “active” patient.	The number of active, confirmed HIV-infected children who have had a visit during each 3 month quarter	Number of patients with at least 1 visit in the past 6 months
Immunologic Monitoring	A CD4 test measures a patient’s level of immune suppression. All CD4 test results and date of tests during the review period should be recorded.	The number of children with a CD4 test (% or count) during the past 6 months	The number of children with at least 1 visit during the past 6 months
ARV Therapy	Proportion of children on ART out of the total number of children who meet MoH eligibility criteria*	The number of children on ART	The total number of children receiving care in the hospital at least 2 months who meet MoH eligibility criteria for ART*
ART Adherence	Adherence to treatment is usually measured by pill count or self report. Pharmacy refills may also be measured	The number of HIV children who have had an adherence assessment in every visit in the last 3 months	The number of children on ART who have been seen as least once in the past 6 months
Cotrimoxazole Prophylaxis	Trimethoprim-sulphamethoxazole (Cotrimoxazole, Septrin) taken once daily is recommended as routine prophylaxis for HIV-infected children.	The number of HIV children receiving cotrimoxazole during the last 3 months	The number of HIV children with at least 1 visit during the past 6 months
TB Clinical Symptom Assessment	The national guidelines recommend initial TB screening by questioning for history of TB contact or the existence of a cough of three weeks duration. Depending on the presence of fever and night sweats in the absence of chronic cough, children may be suspected to have TB. Sputum specimens and CXR are recommended. If children are diagnosed with TB and referred to TB clinic, information should be exchanged between HIV and TB providers.	The number of HIV-infected children who have been screened for TB during the last 3 months	The number of HIV-infected children with at least 1 visit in the past 6 months who have not been diagnosed with active TB
TB Diagnostic Evaluation		The number of HIV-infected children who are evaluated by sputum exam and/or CXR	The number of HIV-infected children who have been screened for TB during the last 6 months and are suspected to have TB or have history of TB contact
Referral from PMTCT to care	The proportion of children in care whose referral source was identified as the PMTCT clinic	The number of new children who were referred from PMTCT clinic	New HIV-infected or HIV-exposed children aged 0-14 years old who received care at HIV clinic at least 1 visit during the last 6 months
Growth Monitoring	Proportion of HIV children receiving weight for age (W/A) assessment.	Number of children receiving weight for age assessment during the past 3 months	Total number of children receiving care at least 1 visit during the review period
Malaria Prevention	Insecticide-treated materials (ITMs) include insecticide-treated nets and other materials	The number of children using ITM during the last 3 months	The total number of children receiving care at least 1 visit during the review period

*MoH eligibility criteria: **0-18 months:** HIV-exposed infants with PCR positive and WHO staging 3 or 4 or CD4 ≤20% **>18 months:** HIV-infected children with WHO staging 3 or 4 or CD4≤15% or TLC≤1800 (<5 years) or TLC ≤1200 (5-12 years)